ArticleThe Journal of allergy and clinical immunology2022
Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity.
Article in The Journal of allergy and clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026Review
- Melatonin suppresses ILC2-driven airway hyperreactivity via glutathione-dependent metabolic reprogramming.Frontiers in immunology · 2026Article
- Cathepsin C-driven enhancement of neutrophil extracellular trap formation contributes to acute lung injury.iScience · 2025Article
- The immunology of asthma.Nature immunology · 2025Review
- Is There a Place for Cannabinoids in Asthma Treatment?International journal of molecular sciences · 2025Review
- SIRPα engagement regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism.Cellular & molecular immunology · 2024Article
- CB2 stimulation of adipose resident ILC2s orchestrates immune balance and ameliorates type 2 diabetes mellitus.Cell reports · 2024Article
- The Impact of the CBMolecules (Basel, Switzerland) · 2024Review
- Airway epithelial-derived exosomes induce acute asthma exacerbation after respiratory syncytial virus infection.MedComm · 2024Article
- Piezo1 channels restrain ILC2s and regulate the development of airway hyperreactivity.The Journal of experimental medicine · 2024Article
- LAIR-1 limits macrophage activation in acute inflammatory lung injury.Mucosal immunology · 2023Article
- Cannabinoid receptor 2 signal promotes type 2 immunity in the lung.Cell insight · 2023Article
- PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability.Nature communications · 2022Article
- Crosstalk between ILC2s and Th2 CD4Journal of immunology research · 2022Review
- Expression and Functions of the CBFrontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCannabinoids modulate the activation of immune cells and physiologic processes in the lungs. Group 2 innate lymphoid cells (ILC2s) are central players in type 2 asthma, but how cannabinoids modulate ILC2 activation remains to be elucidated.
objectiveOur goal was to investigate the effects of cannabinoids on ILC2s and their role in asthma.
methodsA combination of cannabinoid receptor (CB)
resultsWe provide evidence that CB
conclusionCollectively, our results define CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.